Results

1–10 of 153 results for Results

Efficacy and Safety of CT-P42 Compared to Reference Aflibercept (AFL) in Diabetic Macular Edema (DME): 24-Week Results From the Phase 3 CT-P42 3.1 Study
David M. Brown, MD
Annual Meeting Talks
2023
Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2023
48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2023
Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2023
Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration With Intravitreal ANX007: Results of the ARCHER Study
Jeffrey S. Heier, MD
Annual Meeting Talks
2023
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results of the Portal 5-year Subgroup Analysis
David J Massop, MD
Annual Meeting Talks
2023
Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
Aflibercept 8 mg for Diabetic Macular Edema: 2-Year Results of the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Annual Meeting Talks
2023
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023